Tag Archives: #AdComm

Thumbs Up, Thumbs Down – Minimizing Votes in AdComms

The FDA Commissioner has said he would like to limit votes in AdComms – is that really a good idea? Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Tagged , , | Leave a comment

Emerging from Emergency – Two COVID-Related Developments This Week

Two announcements occurred this week, both of note and connected only by the fact that they are emblematic of the slow metamorphosis from a COVID emergency world to a post-COVID emergency one. Emergency Ends – First, the Biden Administration announced … Continue reading

Posted in FDA Image, FDA Policy | Tagged , , , , | Comments Off on Emerging from Emergency – Two COVID-Related Developments This Week

When the Going Gets Tough – FDA AdComms in 2022

Through its Human Drugs Advisory Committee process FDA has a vast array of outside experts to consult on matters related to product approval as well as questions about policy or safety issues concerning approved products. The mechanism provides an open … Continue reading

Posted in Advisory Committee Prepapartion | Tagged , , , | Comments Off on When the Going Gets Tough – FDA AdComms in 2022

AdComms – Is FDA Getting Less Advice?

As more drugs are being approved, is FDA getting less advice than in the past? FDA maintains a vast network of outside advisors to provide input and counsel to the agency related to decisions on policy as well as product … Continue reading

Posted in Advisory Committee Prepapartion, FDA Image, FDA Policy | Tagged , , | Comments Off on AdComms – Is FDA Getting Less Advice?

Virtual Reality – FDA and AdComms

Vaccination has been robust. Cities are opening up. Plans are underway for back-to-school. Travel is robust. Offices are cautiously re-opening. There are multiple hallmarks that, whatever the consequences, we are going back to normal. The age of COVID-19 will likely … Continue reading

Posted in Advisory Committee Prepapartion, COVID19, Current Affairs | Tagged , , | Comments Off on Virtual Reality – FDA and AdComms